Captopril and Combination Therapy of Captopril and Pentoxifylline in Reducing Proteinuria in Diabetic Nephropathy

REFERENCES

• World Health Organization Burden of disease project. Available at http://www3.who.int/topics/global_burden_of_disease/en/ (December 2008).
   Google Scholar
• Atkins RC. The changing patterns of chronic kidney disease: The need to develop strategies for prevention relevant to different regions and countries. Kidney Int Suppl. 2005;68 (Suppl. 98):S83–S85.
   Google Scholar
• Graves DT, Kayal RA. Diabetic complications and dysregulated innate immunity. Front Biosci. 2008;13:1227–1239.
   PubMed Web of Science ®Google Scholar
• Keane WF, Lyle PA. Reduction of endpoints in NIDDM with the Angiotensin II Receptor Antagonist Losartan study. Recent advances in management of type 2 diabetes and nephropathy: Lessons from the RENAAL study. Am J Kidney Dis. 2003;41 (Suppl. 1):S22–S25.
   PubMedGoogle Scholar
• Zoja C, Benigni A, Remuzzi G. Protein overload activates proximal tubular cells to release vasoactive and inflammatory mediators. Exp Nephrol. 1999;7:420–428.
   PubMedGoogle Scholar
• Navarro JF, Milena FJ, Mora C, Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: Effect of angiotensin-converting enzyme inhibition and pentoxifylline administration. Am J Nephrol. 2006;26:562–570.
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Remuzzi G. The role of protein traffic in the progression of renal diseases. Annu Rev Med. 2000;51:315–327.
   PubMedGoogle Scholar
• Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int. 1997;51:2–15.
   PubMed Web of Science ®Google Scholar
• de Zeeuw D, Remuzzi G, Parving HH, Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int. 2004;65:2309–2320.
   PubMed Web of Science ®Google Scholar
• Bilous RW, Mauer SM, Sutherland DE, The effects of pancreas transplantation on the glomerular structure of renal allografts in patients with insulin-dependent diabetes. N Engl J Med. 1989;321:80–85.
   PubMed Web of Science ®Google Scholar
• Hasegawa G, Nakano K, Sawada M, Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int. 1991;40:1007–1012.
   PubMed Web of Science ®Google Scholar
• Navarro JF, Mora-Fernández C. The role of TNF-alpha in diabetic nephropathy: Pathogenic and therapeutic implications. Cytokine Growth Factor Rev. 2006;17:441–450.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Morán M, González-González G, Bermúdez-Barba MV, Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria: A double-blind, placebo-controlled randomized trial. Clin Nephrol. 2006;66:3–10.
   PubMedGoogle Scholar
• Solerte SB, Fioravanti M, Patti AL, Pentoxifylline, total urinary protein excretion rate and arterial blood pressure in long-term insulin-dependent diabetic patients with overt nephropathy. Acta Diabetol Lat. 1987;24:229–239.
   PubMedGoogle Scholar
• Navarro JF, Mora C, Muros M, García J. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: A short-term, randomized, controlled trial. J Am Soc Nephrol. 2005;16: 2119–2126.
   PubMed Web of Science ®Google Scholar
• Paap CM, Simpson KS, Horton MW, Schaefer KL, Lassman HB, Sack MR. Multiple-dose pharmacokinetics of pentoxifylline and its metabolites during renal insufficiency. Ann Pharmacother. 1996;30:724–729.
   PubMedGoogle Scholar
• Hostetter TH. Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med. 2001;345:910–912.
   PubMed Web of Science ®Google Scholar
• Hamilton RA, Kane MP, Demers J. Angiotensin-converting enzyme inhibitors and type 2 diabetic nephropathy: A meta-analysis. Pharmacotherapy. 2003;23:909–915.
   PubMedGoogle Scholar
• Berl T. Angiotensin-converting enzyme inhibitors versus AT1 receptor antagonist in cardiovascular and renal protection: The case for AT1 receptor antagonist. J Am Soc Nephrol. 2004; 15(Suppl. 1):S71–S76.
   Google Scholar
• Casas JP, Chua W, Loukogeorgakis S, Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: Systematic review and meta-analysis. Lancet. 2005;366:2026–2033.
   PubMed Web of Science ®Google Scholar
• Barnett AH, Bain SC, Bouter P, Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351: 1952–1961.
   PubMed Web of Science ®Google Scholar
• Siebenhofer A, Plank J, Horvath K, Angiotensin receptor blockers as anti-hypertensive treatment for patients with diabetes mellitus: Meta-analysis of controlled double-blind randomized trials. Diabet Med. 2004;21:18–25.
   PubMedGoogle Scholar
• Adler AI, Stratton IM, Neil HA, Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study. BMJ. 2000;321:412–419.
   PubMed Web of Science ®Google Scholar
• Aminorroaya A, Janghorbani M, Rezvanian H, Aminian T, Gharavi M, Amini M. Comparison of the effect of pentoxifylline and captopril on proteinuria in patients with type 2 diabetes mellitus. Nephron Clin Pract. 2005;99:73–77.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Morán M, Guerrero-Romero F. Pentoxifylline is as effective as captopril in the reduction of microalbuminuria in non-hypertensive type 2 diabetic patients—a randomized, equivalent trial. Clin Nephrol. 2005;64:91–97.
   PubMed Web of Science ®Google Scholar
• McCormick BB, Sydor A, Akbari A, Fergusson D, Doucette S, Knoll G. The effect of pentoxifylline on proteinuria in diabetic kidney disease: A meta-analysis. Am J Kidney Dis. 2008;52:454–463.
   PubMed Web of Science ®Google Scholar
• Harmankaya O, Seber S, Yilmaz M. Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients. Ren Fail. 2003;25:465–470.
   PubMed Web of Science ®Google Scholar
• Berl T, Hunsicker LG, Lewis JB, Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol. 2005;16: 2170–2179.
   PubMed Web of Science ®Google Scholar
• Eijkelkamp WB, Zhang Z, Remuzzi G, Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: Post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol. 2007;18:1540–1546.
   PubMed Web of Science ®Google Scholar